232 related articles for article (PubMed ID: 32949229)
41. Associations of Green Tea Consumption and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
Ma YH; Wu JH; Xu W; Shen XN; Wang HF; Hou XH; Cao XP; Bi YL; Dong Q; Feng L; Tan L; Yu JT
J Alzheimers Dis; 2020; 77(1):411-421. PubMed ID: 32804140
[TBL] [Abstract][Full Text] [Related]
42. Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects.
Osorio RS; Ducca EL; Wohlleber ME; Tanzi EB; Gumb T; Twumasi A; Tweardy S; Lewis C; Fischer E; Koushyk V; Cuartero-Toledo M; Sheikh MO; Pirraglia E; Zetterberg H; Blennow K; Lu SE; Mosconi L; Glodzik L; Schuetz S; Varga AW; Ayappa I; Rapoport DM; de Leon MJ
Sleep; 2016 Jun; 39(6):1253-60. PubMed ID: 26951396
[TBL] [Abstract][Full Text] [Related]
43. Low soluble amyloid-β 42 is associated with smaller brain volume in Parkinson's disease.
Espay AJ; Lafontant DE; Poston KL; Caspell-Garcia C; Marsili L; Cho HR; McDaniel C; Kim N; Coffey CS; Mahajan A; Ezzat K; Sturchio A;
Parkinsonism Relat Disord; 2021 Nov; 92():15-21. PubMed ID: 34656902
[TBL] [Abstract][Full Text] [Related]
44. Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease.
Buddhala C; Campbell MC; Perlmutter JS; Kotzbauer PT
Neurobiol Aging; 2015 Jan; 36(1):476-84. PubMed ID: 25212463
[TBL] [Abstract][Full Text] [Related]
45. CSF α-Synuclein and Tau as Biomarkers for Dementia With Lewy Bodies: A Systematic Review and Meta-analysis.
Zhang Q; Li J; Quan W; Liu L; Qin Y; Pei X; Su H; Xu J; Chen J
Alzheimer Dis Assoc Disord; 2022 Oct-Dec 01; 36(4):368-373. PubMed ID: 36183420
[TBL] [Abstract][Full Text] [Related]
46. Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease.
Ibanez L; Bahena JA; Yang C; Dube U; Farias FHG; Budde JP; Bergmann K; Brenner-Webster C; Morris JC; Perrin RJ; Cairns NJ; O'Donnell J; Álvarez I; Diez-Fairen M; Aguilar M; Miller R; Davis AA; Pastor P; Kotzbauer P; Campbell MC; Perlmutter JS; Rhinn H; Harari O; Cruchaga C; Benitez BA
Acta Neuropathol Commun; 2020 Nov; 8(1):196. PubMed ID: 33213513
[TBL] [Abstract][Full Text] [Related]
47. Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease.
Shi M; Tang L; Toledo JB; Ginghina C; Wang H; Aro P; Jensen PH; Weintraub D; Chen-Plotkin AS; Irwin DJ; Grossman M; McCluskey L; Elman LB; Wolk DA; Lee EB; Shaw LM; Trojanowski JQ; Zhang J
Alzheimers Dement; 2018 Aug; 14(8):1052-1062. PubMed ID: 29604263
[TBL] [Abstract][Full Text] [Related]
48. Simultaneous quantification of tau and α-synuclein in cerebrospinal fluid by high-resolution mass spectrometry for differentiation of Lewy Body Dementia from Alzheimer's Disease and controls.
Viodé A; Epelbaum S; Benyounes I; Verny M; Dubois B; Junot C; Fenaille F; Lamari F; Becher F
Analyst; 2019 Oct; 144(21):6342-6351. PubMed ID: 31553333
[TBL] [Abstract][Full Text] [Related]
49. CSF α-synuclein, tau, and amyloid β in Parkinson's disease.
Shi M; Zhang J
Lancet Neurol; 2011 Aug; 10(8):681; author's reply 681-3. PubMed ID: 21777821
[No Abstract] [Full Text] [Related]
50. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.
Shi M; Bradner J; Hancock AM; Chung KA; Quinn JF; Peskind ER; Galasko D; Jankovic J; Zabetian CP; Kim HM; Leverenz JB; Montine TJ; Ginghina C; Kang UJ; Cain KC; Wang Y; Aasly J; Goldstein D; Zhang J
Ann Neurol; 2011 Mar; 69(3):570-80. PubMed ID: 21400565
[TBL] [Abstract][Full Text] [Related]
51. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
Abdelnour C; van Steenoven I; Londos E; Blanc F; Auestad B; Kramberger MG; Zetterberg H; Mollenhauer B; Boada M; Aarsland D;
Mov Disord; 2016 Aug; 31(8):1203-8. PubMed ID: 27296778
[TBL] [Abstract][Full Text] [Related]
52. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease.
Tateno F; Sakakibara R; Kawai T; Kishi M; Murano T
Alzheimer Dis Assoc Disord; 2012; 26(3):213-6. PubMed ID: 22037599
[TBL] [Abstract][Full Text] [Related]
53. Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents.
Calderón-Garcidueñas L; Avila-Ramírez J; Calderón-Garcidueñas A; González-Heredia T; Acuña-Ayala H; Chao CK; Thompson C; Ruiz-Ramos R; Cortés-González V; Martínez-Martínez L; García-Pérez MA; Reis J; Mukherjee PS; Torres-Jardón R; Lachmann I
J Alzheimers Dis; 2016 Sep; 54(2):597-613. PubMed ID: 27567860
[TBL] [Abstract][Full Text] [Related]
54. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
Goldman JG; Andrews H; Amara A; Naito A; Alcalay RN; Shaw LM; Taylor P; Xie T; Tuite P; Henchcliffe C; Hogarth P; Frank S; Saint-Hilaire MH; Frasier M; Arnedo V; Reimer AN; Sutherland M; Swanson-Fischer C; Gwinn K; ; Kang UJ
Mov Disord; 2018 Feb; 33(2):282-288. PubMed ID: 29205509
[TBL] [Abstract][Full Text] [Related]
55. Associations of Alcohol Consumption with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
Wang ZT; Li KY; Tan CC; Xu W; Shen XN; Cao XP; Wang P; Bi YL; Dong Q; Tan L; Yu JT
J Alzheimers Dis; 2021; 82(3):1045-1054. PubMed ID: 34151793
[TBL] [Abstract][Full Text] [Related]
56. Differential diagnosis between Alzheimer's disease and other dementias: Role of cerebrospinal fluid biomarkers.
Farotti L; Sepe FN; Toja A; Rinaldi R; Parnetti L
Clin Biochem; 2019 Oct; 72():24-29. PubMed ID: 30998910
[No Abstract] [Full Text] [Related]
57. Misfolded α-Synuclein in Cerebrospinal Fluid of Contact Sport Athletes.
Vasilevskaya A; Martinez-Valbuena I; Anastassiadis C; Taghdiri F; Khodadadi M; Tarazi A; Green R; Colella B; Wennberg R; Mikulis D; Davis KD; Kovacs GG; Tator C; Tartaglia MC
Mov Disord; 2023 Nov; 38(11):2125-2131. PubMed ID: 37792643
[TBL] [Abstract][Full Text] [Related]
58. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
[TBL] [Abstract][Full Text] [Related]
59. Associations of sleep disorders with cerebrospinal fluid α-synuclein in prodromal and early Parkinson's disease.
Wang XT; Yu H; Liu FT; Zhang C; Ma YH; Wang J; Dong Q; Tan L; Wang H; Yu JT
J Neurol; 2022 May; 269(5):2469-2478. PubMed ID: 34605986
[TBL] [Abstract][Full Text] [Related]
60. CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.
Oosterveld LP; Verberk IMW; Majbour NK; El-Agnaf OM; Weinstein HC; Berendse HW; Teunissen CE; van de Berg WDJ
Mov Disord; 2020 Feb; 35(2):288-295. PubMed ID: 31737952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
